Multimodality Treatment in Adult Patients with High-risk Soft-tissue Sarcomas

2006 ◽  
Vol 5 (1) ◽  
pp. 2-7 ◽  
Author(s):  
Bernd Kasper ◽  
Evelyn Kuehl ◽  
Ludger Bernd ◽  
Anthony D. Ho ◽  
Gerlinde Egerer
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Multimodality Treatment ◽  
Adult Patients

Predictive value of MRP-1 in localized high-risk soft tissue sarcomas: a translational research associated to ISG-STS 1001 randomized phase III trial.

2021 ◽  
pp. molcanther.0315.2021
Author(s):  
Javier Martín-Broto ◽  
Maria Lopez-Alvarez ◽  
David S Moura ◽  
Rafael Ramos ◽  
Paola Collini ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Translational Research ◽  
Predictive Value ◽  
Soft Tissue Sarcomas ◽  
Phase Iii ◽  
Phase Iii Trial

Expression of the mdr1 gene in bone and soft tissue sarcomas of adult patients

1993 ◽  
Vol 29 (14) ◽  
pp. 1979-1981 ◽  
Author(s):  
Ulrike Stein ◽  
Volker Wunderlich ◽  
Wolfgang Haensch ◽  
Peter Schmidt-Peter
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Adult Patients ◽  
Mdr1 Gene

scholarly journals Progress in the Systemic Treatment of Advanced Soft-Tissue Sarcomas

1998 ◽  
Vol 5 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Scott H. Okuno ◽  
John H. Edmonson
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Systemic Treatment ◽  
Soft Tissue Sarcomas ◽  
Multimodality Treatment ◽  
Clinical Situation ◽  
Controlled Clinical Trials ◽  
Systemic Treatments ◽  
Review Current ◽  
Systemic Therapies

Background: Despite the plethora of chemotherapeutic remedies for advanced soft-tissue sarcomas, little evidence has developed to indicate that these efforts have been curative. No controlled comparison has yet proven that patients receiving multidrug regimens survive longer than those receiving doxorubicin alone. Methods: The authors review current systemic treatments and then discuss some investigational efforts now in progress. Also, they seek to demonstrate how the therapies currently available can be integrated with surgery and radiation therapy to accomplish more than might be anticipated from chemotherapy alone. Results: While working to develop better systemic therapies for advanced soft-tissue sarcomas, the integrated use of our best chemotherapy regimens in combination with selected surgical and radiotherapy efforts may provide patients with the best available therapy. Some recent observations involving the use of molgramostim plus chemotherapy have been intriguing. Conclusions: Progress in the systemic treatment of advanced soft-tissue sarcomas may be gradual, but it is real. Our daily challenge is to be certain that we offer each patient the best available multimodality treatment applicable to his or her clinical situation. Molgramostim should be made available for further study with chemotherapy in controlled clinical trials.

scholarly journals The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas

2001 ◽  
Vol 84 (2) ◽  
pp. 244-252 ◽  
Author(s):  
S Maula ◽  
R L Huuhtanen ◽  
C P Blomqvist ◽  
T A Wiklund ◽  
P Laurila ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Local Recurrence ◽  
Adhesion Molecule ◽  
Soft Tissue Sarcomas

scholarly journals Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas

Cancer ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2432-2439 ◽  
Author(s):  
Christopher W. Ryan ◽  
Anthony G. Montag ◽  
Janet R. Hosenpud ◽  
Brian Samuels ◽  
James B. Hayden ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Hypofractionated Radiotherapy ◽  
Histologic Response
Sign in / Sign up

Export Citation Format

Share Document